Spiro[2,4-dihydronaphthalene-3,3'-cyclohexene]-1-one | 388601-35-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: Spiro[2,4-dihydronaphthalene-3,3'-cyclohexene]-1-one
• CAS: 388601-35-2
• 化学式: C₁₅H₁₆O
• 分子量: 212.291
• InChiKey: FQXWAFRKJVLHTC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  Spiro[2,4-dihydronaphthalene-3,3'-cyclohexene]-1-one 在 sodium azide 、 三氟乙酸 作用下， 以65%的产率得到spiro[3,5-dihydro-1H-1-benzazepine-4,3'-cyclohexene]-2-one
  参考文献：
  名称：

  Synthesis and evaluation of spirobenzazepines as potent vasopressin receptor antagonists

  摘要：

  A novel series of spirobenzazepines was synthesized and evaluated for V-1a and V-2 receptor antagonist activity. Compounds 8b, 8i, and 8k have shown selective V-1a receptor antagonist activity. Compounds 8p and 8q were shown to be dual V-1a/V-2 receptor antagonists. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.02.103
• 作为产物：
  描述：

  苄基溴化镁 在 sodium chlorite 、 lithium aluminium tetrahydride 、 sodium hydride 、 碳酸氢钠 、 sodium phosphate 、 三氟乙酸 、 三氟乙酸酐 作用下， 以 四氢呋喃 、 萘烷 为溶剂， 生成 Spiro[2,4-dihydronaphthalene-3,3'-cyclohexene]-1-one
  参考文献：
  名称：

  Synthesis and evaluation of spirobenzazepines as potent vasopressin receptor antagonists

  摘要：

  A novel series of spirobenzazepines was synthesized and evaluated for V-1a and V-2 receptor antagonist activity. Compounds 8b, 8i, and 8k have shown selective V-1a receptor antagonist activity. Compounds 8p and 8q were shown to be dual V-1a/V-2 receptor antagonists. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.02.103

文献信息

• Nonpeptide substituted spirobenzoazepines as vasopressin antagonists
  申请人：Chen H.K. Robert

  公开号：US20070117790A1

  公开（公告）日：2007-05-24

  The invention is directed to nonpeptide substituted benzodiazepines of Formula I, wherein A, X, n, R 1 , R 2 , R 3 , R 4 , R 5 , a and b are as described in the specification, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, cerebral edema and ischemia, stroke, thrombosis, or water retention are also disclosed.

  本发明涉及一种非肽替代苯二氮平类化合物，其化学式为I，其中A、X、n、R1、R2、R3、R4、R5、a和b如规范中所述，用作抗利尿激素受体拮抗剂，用于治疗与利尿激素受体活性相关的疾病，如涉及增加血管阻力和心脏衰竭的疾病。还公开了包含化合物I的药物组合物和治疗高血压、充血性心力衰竭、冠状动脉痉挛、心肌缺血、肝硬化、肾脏血管痉挛、肾功能衰竭、脑水肿和缺血、中风、血栓或水肿等疾病的方法。
• US7238687B2
  申请人：——

  公开号：US7238687B2

  公开（公告）日：2007-07-03
• US7365062B2
  申请人：——

  公开号：US7365062B2

  公开（公告）日：2008-04-29
• US7691844B2
  申请人：——

  公开号：US7691844B2

  公开（公告）日：2010-04-06
• Synthesis and evaluation of spirobenzazepines as potent vasopressin receptor antagonists
  作者：Min Amy Xiang、Robert H. Chen、Keith T. Demarest、Joseph Gunnet、Richard Look、William Hageman、William V. Murray、Donald W. Combs、Mona Patel

  DOI：10.1016/j.bmcl.2004.02.103

  日期：2004.6

  A novel series of spirobenzazepines was synthesized and evaluated for V-1a and V-2 receptor antagonist activity. Compounds 8b, 8i, and 8k have shown selective V-1a receptor antagonist activity. Compounds 8p and 8q were shown to be dual V-1a/V-2 receptor antagonists. (C) 2004 Elsevier Ltd. All rights reserved.